Myxoma virus and oncolytic virotherapy: A new biologic weapon in the war against cancer

Marianne M. Stanford, Douglas McFadden

Research output: Contribution to journalReview article

56 Citations (Scopus)

Abstract

Oncolytic virotherapy is an innovative alternative to more conventional cancer therapies. The ability of some viruses to specifically target and kill malignant cancerous cells while leaving normal tissue unscathed has opened a large repertoire of new and selective cancer killing therapeutic candidates. Poxviruses, such as vaccinia virus, have a long history of use in humans as live vaccines and have more recently been studied as potential platforms for delivery of immunotherapeutics and attenuated variants of vaccinia have been explored as oncolytic candidates. In contrast, the poxvirus myxoma virus is a novel oncolytic candidate that has no history of use in humans directly, as it has a distinct and absolute host species tropism to lagomorphs (rabbits). Myxoma virus has been recently shown to be able to also selectively infect and kill human tumor cells, a unique tropism that is linked to dysregulated intracellular signalling pathways found in the majority of human cancers. This review outlines the existing knowledge on the tropism of myxoma virus for human cancer cells, as well as preclinical data exhibiting its ability to infect and clear tumors in animal models of cancer. This is an exciting new therapeutic option for treating cancer, and myxoma virus joins a growing group of oncolytic virus candidates that are being developed as a new class of cancer therapies in man.

Original languageEnglish (US)
Pages (from-to)1415-1425
Number of pages11
JournalExpert Opinion on Biological Therapy
Volume7
Issue number9
DOIs
StatePublished - Sep 1 2007
Externally publishedYes

Fingerprint

Myxoma virus
Oncolytic Virotherapy
Weapons
Viruses
Neoplasms
Poxviridae
Tropism
Tumors
Cells
Viral Tropism
Lagomorpha
Oncolytic Viruses
Warfare
Vaccinia
Vaccinia virus
Therapeutics
Animals
Vaccines
Tissue
Animal Models

Keywords

  • Akt
  • mTOR
  • Oncolysis
  • Poxvirus
  • Rapamycin
  • Virotherapy

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Myxoma virus and oncolytic virotherapy : A new biologic weapon in the war against cancer. / Stanford, Marianne M.; McFadden, Douglas.

In: Expert Opinion on Biological Therapy, Vol. 7, No. 9, 01.09.2007, p. 1415-1425.

Research output: Contribution to journalReview article

@article{1ee3f93bc716411aab3c0e2a210dd057,
title = "Myxoma virus and oncolytic virotherapy: A new biologic weapon in the war against cancer",
abstract = "Oncolytic virotherapy is an innovative alternative to more conventional cancer therapies. The ability of some viruses to specifically target and kill malignant cancerous cells while leaving normal tissue unscathed has opened a large repertoire of new and selective cancer killing therapeutic candidates. Poxviruses, such as vaccinia virus, have a long history of use in humans as live vaccines and have more recently been studied as potential platforms for delivery of immunotherapeutics and attenuated variants of vaccinia have been explored as oncolytic candidates. In contrast, the poxvirus myxoma virus is a novel oncolytic candidate that has no history of use in humans directly, as it has a distinct and absolute host species tropism to lagomorphs (rabbits). Myxoma virus has been recently shown to be able to also selectively infect and kill human tumor cells, a unique tropism that is linked to dysregulated intracellular signalling pathways found in the majority of human cancers. This review outlines the existing knowledge on the tropism of myxoma virus for human cancer cells, as well as preclinical data exhibiting its ability to infect and clear tumors in animal models of cancer. This is an exciting new therapeutic option for treating cancer, and myxoma virus joins a growing group of oncolytic virus candidates that are being developed as a new class of cancer therapies in man.",
keywords = "Akt, mTOR, Oncolysis, Poxvirus, Rapamycin, Virotherapy",
author = "Stanford, {Marianne M.} and Douglas McFadden",
year = "2007",
month = "9",
day = "1",
doi = "10.1517/14712598.7.9.1415",
language = "English (US)",
volume = "7",
pages = "1415--1425",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Myxoma virus and oncolytic virotherapy

T2 - A new biologic weapon in the war against cancer

AU - Stanford, Marianne M.

AU - McFadden, Douglas

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Oncolytic virotherapy is an innovative alternative to more conventional cancer therapies. The ability of some viruses to specifically target and kill malignant cancerous cells while leaving normal tissue unscathed has opened a large repertoire of new and selective cancer killing therapeutic candidates. Poxviruses, such as vaccinia virus, have a long history of use in humans as live vaccines and have more recently been studied as potential platforms for delivery of immunotherapeutics and attenuated variants of vaccinia have been explored as oncolytic candidates. In contrast, the poxvirus myxoma virus is a novel oncolytic candidate that has no history of use in humans directly, as it has a distinct and absolute host species tropism to lagomorphs (rabbits). Myxoma virus has been recently shown to be able to also selectively infect and kill human tumor cells, a unique tropism that is linked to dysregulated intracellular signalling pathways found in the majority of human cancers. This review outlines the existing knowledge on the tropism of myxoma virus for human cancer cells, as well as preclinical data exhibiting its ability to infect and clear tumors in animal models of cancer. This is an exciting new therapeutic option for treating cancer, and myxoma virus joins a growing group of oncolytic virus candidates that are being developed as a new class of cancer therapies in man.

AB - Oncolytic virotherapy is an innovative alternative to more conventional cancer therapies. The ability of some viruses to specifically target and kill malignant cancerous cells while leaving normal tissue unscathed has opened a large repertoire of new and selective cancer killing therapeutic candidates. Poxviruses, such as vaccinia virus, have a long history of use in humans as live vaccines and have more recently been studied as potential platforms for delivery of immunotherapeutics and attenuated variants of vaccinia have been explored as oncolytic candidates. In contrast, the poxvirus myxoma virus is a novel oncolytic candidate that has no history of use in humans directly, as it has a distinct and absolute host species tropism to lagomorphs (rabbits). Myxoma virus has been recently shown to be able to also selectively infect and kill human tumor cells, a unique tropism that is linked to dysregulated intracellular signalling pathways found in the majority of human cancers. This review outlines the existing knowledge on the tropism of myxoma virus for human cancer cells, as well as preclinical data exhibiting its ability to infect and clear tumors in animal models of cancer. This is an exciting new therapeutic option for treating cancer, and myxoma virus joins a growing group of oncolytic virus candidates that are being developed as a new class of cancer therapies in man.

KW - Akt

KW - mTOR

KW - Oncolysis

KW - Poxvirus

KW - Rapamycin

KW - Virotherapy

UR - http://www.scopus.com/inward/record.url?scp=34748903753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748903753&partnerID=8YFLogxK

U2 - 10.1517/14712598.7.9.1415

DO - 10.1517/14712598.7.9.1415

M3 - Review article

C2 - 17727330

AN - SCOPUS:34748903753

VL - 7

SP - 1415

EP - 1425

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 9

ER -